Cleared Traditional

K920880 - BRAINSCAN BRACHYTHERAPY MODULE

K920880 is an FDA 510(k) clearance for BRAINSCAN BRACHYTHERAPY MODULE, manufactured by Brainlab. The device is a Class 2 Radiology device with product code KXK cleared through the Traditional 510(k) pathway after a 308-day FDA review.

K920880 · Brainlab · Radiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1992
Decision
308d
Days
Class 2
Risk

K920880 is an FDA 510(k) clearance for the BRAINSCAN BRACHYTHERAPY MODULE. Classified as Source, Brachytherapy, Radionuclide (product code KXK), Class II - Special Controls.

Submitted by Brainlab (West Germany, DE). The FDA issued a Cleared decision on December 30, 1992 after a review of 308 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.5730 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Radiology review framework, consistent with the majority of Class II 510(k) submissions.

FDA 510(k) Submission Details - K920880

510(k) Number K920880 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 26, 1992
Decision Date December 30, 1992
Days to Decision 308 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
201d slower than avg
Panel avg: 107d · This submission: 308d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

KXK Device Classification - Class 2, Special Controls

Product Code KXK Source, Brachytherapy, Radionuclide
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 892.5730
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Radiology devices follow this clearance model.

Regulatory Peers - KXK Source, Brachytherapy, Radionuclide

All 150
Devices cleared under the same product code (KXK) and FDA review panel - the closest regulatory comparables to K920880.
RADIOACTIVE SAMARIUM 145 SEEDS/SOURCES #2341-2345
K932242 · Best Industries · Jul 1993
RADIOACTIVE CESIUM-131 SEEDS/SOURCES
K924261 · Best Industries · Jun 1993
RADIOACTIVE PALLADIUM 103 SEEDS/SOURCES
K930570 · Best Industries · Jun 1993
IR-192 IMPLANT -- MODIFICATION
K923130 · Omnitron Intl., Inc. · Sep 1992
1-125 ENDOSEED
K914825 · Endo Technic Corp. · Mar 1992
I-125 SEEDS CODE: 6702
K915156 · Medi-Physics Inc. Dba Nycomed Amersham Imaging · Jan 1992
K920880 · BRAINSCAN BRACHYTHERAPY MODULE
Download PDF Brainlab